[1] XIAO W, ZHAO S, SHEN F, et al.Overexpression of CD147 is associated with poor prognosis, tumor cell migration and ERK signaling pathway activation in hepatocellular carcinoma[J].Exp Ther Med, 2017, 14(3):2637. doi: 10.3892/etm.2017.4818
[2] CAO W, SHAMA M, IMAM R, et al.Study on diagnostic values of astrocyte elevated gene 1(AEG-1) and glypican 3(GPC-3) in hepatocellular carcinoma[J].Am J Clin Pathol, 2019, 152(5):647. doi: 10.1093/ajcp/aqz086
[3] WEE A.Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics[J].Appl Immunohistochem Mol Morphol, 2006, 14(3):266. doi: 10.1097/00129039-200609000-00003
[4] WANG HL, ANATELLI F, ZHAI QJ, et al.Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions[J].Arch Pathol Lab Med, 2008, 132(11):1723.
[5] EL-SAADANY S, EL-DEMERDASH T, HELMY A, et al.Diagnostic value of Glypican-3 for hepatocellular carcinomas[J].Asian Pac J Cancer Prev, 2018, 19(3):811.
[6] COSTON WM, LOERA S, LAU SK, et al.Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry[J].Am J Surg Pathol, 2008, 32(3):433.
[7] DI TOMMASO L, DESTRO A, SEOK JK, et al.The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma[J].J Hepatol, 2009, 50(4):746. doi: 10.1016/j.jhep.2008.11.014
[8] DI TOMMASO L, DESTRO A, FABBRIS V, et al.Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma[J].Hepatology, 2011, 53(5):1549. doi: 10.1002/hep.24218
[9] CUI X, LI Z, GAO PJ, et al.Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation[J].Hepatobiliary Pancreat Dis Int, 2015, 14(2):157.
[10] GERAMIZADEH B, SEIRFAR N.Diagnostic value of Arginase-1 and Glypican-3 in differential diagnosis of hepatocellular carcinoma, cholangiocarcinoma and metastatic carcinoma of liver[J].Hepat Mon, 2015, 15(7):e30336.
[11] 王娟, 张曙光, 孙颖, 等.免疫组化检测GPC-3与CK-19在肝细胞癌诊断中的应用价值[J].临床和实验医学杂志, 2017, 16(14):1398. doi: 10.3969/j.issn.1671-4695.2017.14.016
[12] KADOTA K, VILLENA-VARGAS J, NITADORI JI, et al.Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma[J].Ann Surg Oncol, 2015, 22(9):3136. doi: 10.1245/s10434-015-4374-x
[13] DING P, ZHANG X, JIN S, et al.CD147 functions as the signaling receptor for extracellular divalent copper in hepatocellular carcinoma cells[J].Oncotarget, 2017, 8(31):51151.
[14] ZHU R, ZHANG CG, LIU Y, et al.CD147 monoclonal antibody mediated by chitosan nanoparticles loaded with adhederin enhances antineoplastic activity and cellular uptake in liver cancer cells[J].Sci Rep, 2015, 5:17904.
[15] 杨捷, 周晴, 徐小勇, 等.CD147与肝癌关系的研究进展[J].中国普外基础与临床杂志, 2015, 22(10):1279. doi: 10.7507/1007-9424.20150333
[16] YONG YL, ZHANG RY, LIU ZK, et al.Gamma-secretase complex-dependent intramembrane proteolysis of CD147 regulates the Notch1 signaling pathway in hepatocellular carcinoma[J].J Pathol, 2019, 249(2):255. doi: 10.1002/path.5316
[17] QI S, SU L, LI J, et al.YIPF2 is a novel Rab-GDF that enhances HCC malignant phenotypes by facilitating CD147 endocytic recycle[J].Cell Death Dis, 2019, 10(6):462. doi: 10.1038/s41419-019-1709-8
[18] JIN J, WANG SJ, CUI J, et al.Hypo-phosphorylated CD147 promotes migration and invasion of hepatocellular carcinoma cells and predicts a poor prognosis[J].Cell Oncol (Dordr), 2019, 42(4):537.
[19] WANG L, LI S, YU X, et al.α2, 6-Sialylation promotes immune escape in hepatocarcinoma cells by regulating T cell functions and CD147/MMP signaling[J].J Physiol Biochem, 2019, 75(2):199. doi: 10.1007/s13105-019-00674-8
[20] VON MINCKWITZ G, PFITZNER BM, MVLLER V, et al.21P*Expression of CD138/syndecan-1 in triple-negative breast Cancer-correlative study of GeparSixto[J].Annals Oncol, 2015, 26(suppl 3):iii6.
[21] MARTELLO M, REMONDINI D, BORSI E, et al.Abstract 3189:The alternate activation of hedgehog pathway, either in CD138+ or in CD138-CD19+ multiple myeloma primary cells, impacts on disease outcome[J].Cancer Research, 2016, 76(14 Suppl):3189.